Ibifen (Ketoprofen)

Ketoprofen works by reversibly inhibiting the cyclooxygenase enzymes COX‑1 and COX‑2, which are essential for converting arachidonic acid into prostaglandins. By lowering prostaglandin levels, it reduces peripheral sensitisation of pain receptors, diminishes inflammation, and limits swelling and fever associated with tissue injury.

The appropriate dose of Ibifen is determined by the prescribing clinician based on the patient’s condition, severity of pain, and overall health status. Dosage may vary, and the prescriber will select the specific amount and frequency that best fits the therapeutic need.

Safety data for ketoprofen use in pregnancy and lactation are limited. It is generally advised to avoid ketoprofen during the first trimester and throughout breastfeeding unless the potential benefit outweighs the risk. Clinicians should assess each case individually and consider alternative therapies when possible.

To order Ibifen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Ibifen (ketoprofen) belongs to the NSAID class and shares a similar mechanism with drugs such as diclofenac and ibuprofen. Compared with some alternatives, ketoprofen often provides a slightly longer duration of analgesia and stronger anti‑inflammatory activity, but it may also carry a comparable risk of gastrointestinal and renal adverse effects.

Ibifen should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. The product should remain in its original packaging until use to maintain stability and sterility.

Ibifen is supplied as a sterile injectable solution for intramuscular injection. The injection is performed by a qualified healthcare professional, typically into a large muscle such as the gluteus maximus, following aseptic technique and the dosage prescribed by the clinician.

Serious risks associated with Ibifen include gastrointestinal ulceration or bleeding, acute renal impairment, and severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome. Patients should be monitored for signs of abdominal pain, blood in stool, sudden loss of kidney function, or any allergic symptoms and seek immediate medical attention if they occur.

Ibifen should be avoided in individuals with known hypersensitivity to ketoprofen or other NSAIDs, those with active peptic ulcer disease, severe renal or hepatic impairment, and patients receiving anticoagulant therapy where bleeding risk is high. Caution is also advised for the elderly and for patients with cardiovascular disease.